NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

The longs are excited about the coming enormous firework show. You cannot sense how excited we are?

I can sense how agitated you have been ever since the company filed for approval. Over 90% of your posts were after the filing. Are you trapped?

Have you read the 10Q carefully? Roswell is going to run a tumor-agnostic trial which will cover four refractory cancers. Have you taken a look at the trial record? The trial was started in 2019 and now the trial will have significant expansion to cover four cancers. Given that the in-license technology will be used in this trial, you don't think NWBO and Roswell should have discussion about the targets? If Roswell can run a tumor-agnostic trial, would NWBO run a tumor-agnostic trial too with much tougher targets?

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
https://clinicaltrials.gov/study/NCT04093323

As previously reported, the Company entered into exclusive licenses from Roswell Park Cancer Center and the University of Pittsburgh, covering a large portfolio dendritic cell technologies developed over the course of more than 27 years of work by a leading team of dendritic cell experts, as well as 5 new patent families. The in-licensed technologies in the combined portfolios are currently in three Phase 2 clinical trials that are fully funded by grants and fully being carried out by the investigators. These Phase 2 trials are ongoing and one of them has been approved for a significant expansion in scope by the grant funding agency. That trial is testing an in-licensed dendritic cell treatment in melanoma that is refractory (unresponsive) to checkpoint inhibitor drugs. That dendritic cell treatment aims at a set of targets on abnormal blood vessels that are associated with tumors. As such, that dendritic cell treatment is anticipated to be tumor-agnostic and potentially applicable to most types of solid tumors. The expansion of the trial scope that has been approved is to add refractory lung, breast and bladder cancers to the trial in addition to refractory melanoma.